Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy
Copyright © 2023. Published by Elsevier Inc..
Low response rate of immune checkpoint blockade (ICB) has limited its clinical application. A promising strategy to overcome this limitation is the use of therapeutic cancer vaccines, which aim to induce robust immune responses that synergize with ICB through immune enhancement and immune normalization strategies. Herein, we developed a combination immunotherapy by combining nano-vaccines consisting of whole tumor cell lysates/CpG liposomes (LCLs) with an anti-PD-L1 loaded lipid gel (aPD-L1LG). The LCLs were fabricated using cationic liposomes, while the lipid gels (LGs) were prepared by using soybean phosphatidylcholine (SPC) and glycerol dioleate (GDO). Subcutaneous administration of LCLs successfully activated dendritic cells (DCs), and intratumoral administration of anti-PD-L1@LG ensured sustained ICB activity. These results demonstrated that this combination immunotherapy enhanced anti-tumor efficacy and prolonged the survival time in melanoma by activating systemic anti-tumor immune responses. These findings highlight the potential of this rational design as a promising strategy for tumor treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Nanomedicine : nanotechnology, biology, and medicine - 53(2023) vom: 25. Sept., Seite 102693 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Qian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Combination immunotherapy |
|---|
| Anmerkungen: |
Date Completed 25.09.2023 Date Revised 27.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nano.2023.102693 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358452414 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358452414 | ||
| 003 | DE-627 | ||
| 005 | 20231226074754.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nano.2023.102693 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358452414 | ||
| 035 | |a (NLM)37343780 | ||
| 035 | |a (PII)S1549-9634(23)00044-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Qian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2023 | ||
| 500 | |a Date Revised 27.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a Low response rate of immune checkpoint blockade (ICB) has limited its clinical application. A promising strategy to overcome this limitation is the use of therapeutic cancer vaccines, which aim to induce robust immune responses that synergize with ICB through immune enhancement and immune normalization strategies. Herein, we developed a combination immunotherapy by combining nano-vaccines consisting of whole tumor cell lysates/CpG liposomes (LCLs) with an anti-PD-L1 loaded lipid gel (aPD-L1LG). The LCLs were fabricated using cationic liposomes, while the lipid gels (LGs) were prepared by using soybean phosphatidylcholine (SPC) and glycerol dioleate (GDO). Subcutaneous administration of LCLs successfully activated dendritic cells (DCs), and intratumoral administration of anti-PD-L1@LG ensured sustained ICB activity. These results demonstrated that this combination immunotherapy enhanced anti-tumor efficacy and prolonged the survival time in melanoma by activating systemic anti-tumor immune responses. These findings highlight the potential of this rational design as a promising strategy for tumor treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Combination immunotherapy | |
| 650 | 4 | |a Immune checkpoint blockade | |
| 650 | 4 | |a Lipid gel | |
| 650 | 4 | |a Nano-vaccines | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Sun, Mengjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yanan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Liping |e verfasserin |4 aut | |
| 700 | 1 | |a Zu, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Kuang, Xiaoqin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jianing |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Mingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chunjiayu |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Jiasheng |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Chunmeng |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Yunai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine : nanotechnology, biology, and medicine |d 2005 |g 53(2023) vom: 25. Sept., Seite 102693 |w (DE-627)NLM16062021X |x 1549-9642 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2023 |g day:25 |g month:09 |g pages:102693 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nano.2023.102693 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2023 |b 25 |c 09 |h 102693 | ||